Inspire Medical Systems (INSP) stock is back in focus after the company released second quarter 2026 results and updated its full year guidance on 3 August, along with an update on its share repurchase activity.
See our latest analysis for Inspire Medical Systems.
Despite Inspire Medical Systems updating guidance and completing its buyback program, the stock’s recent momentum has cooled, with the 1-day and 7-day share price returns down 1.89% and 5.09%. This contrasts with a 90-day share price return of 42.57% and a 3-year total shareholder return decline of 73.62%.
If earnings news has you reassessing opportunities in healthcare, it could be a useful time to scan other medical technology and related names through the healthcare focused 44 healthcare AI stocks.
Inspire Medical Systems now trades at a discount to both analyst targets and an estimated fair value after a sharp 90 day rebound. Is the market correctly pricing in the mixed growth and earnings picture, or is it being too cautious?
Most Popular Narrative: 9.5% Overvalued
Inspire Medical Systems last closed at $57.10, while the most widely followed narrative anchors fair value closer to $52.17 using a detailed earnings and reimbursement framework.
The analysts have a consensus price target of $52.17 for Inspire Medical Systems based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $65.0, and the most bearish reporting a price target of just $39.0.
Want to understand why this fair value sits below today’s price yet still assumes meaningful revenue and earnings power over time? The narrative leans on detailed forecasts for top line growth, profitability and the valuation multiple that might apply if those numbers play out. Curious how those moving parts fit together and which assumption really drives the model.
Result: Fair Value of $52.17 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Inspire Medical Systems still faces key risks, including possible reimbursement setbacks and slower Inspire V adoption, which could challenge the current fair value narrative.
Find out about the key risks to this Inspire Medical Systems narrative.
Another View On Inspire Medical Systems Valuation
The analyst narrative frames Inspire Medical Systems as 9.5% overvalued at $57.10 versus a $52.17 fair value. Yet on simple earnings multiples the picture looks different. INSP trades on a P/E of 12.2x, compared with 26.2x for the US Medical Equipment industry and 78.1x for peers. The fair ratio is 18.3x, which is above today’s multiple and raises the question of whether the gap will narrow. Is this discount a sign of caution that proves justified, or is it an indication that the first valuation method is not fully capturing the comparative multiple perspective?
For investors who rely more on comparative ratios, the preferred multiple view raises its own questions about risk and potential outcomes, especially when industry and peer benchmarks sit so far above the current P/E. See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
If the mixed signals around Inspire Medical Systems leave you uncertain, review the data now and shape your own view using the 3 key rewards and 1 important warning sign.
Looking for more investment ideas beyond Inspire Medical Systems?
If Inspire Medical Systems has sharpened your focus, do not stop here. Use Simply Wall Street's screener to uncover fresh stock ideas that fit your goals.
- Target potential mispriced opportunities by comparing quality and value using the 50 high quality undervalued stocks.
- Prioritise resilience and capital preservation by scanning financially sturdy companies through the 83 resilient stocks with low risk scores.
- Hunt for underfollowed prospects with strong fundamentals using the screener containing 18 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com